SAN FRANCISCO, Sept. 21, 2017 /PRNewswire/ -- UNITY
Biotechnology, Inc. ("UNITY"), a privately held biotechnology
company creating therapeutics that prevent, halt, or reverse
numerous diseases of aging, today announced recent additions to its
executive team.
Joining as chief financial officer is Bob Goeltz. Bob was most recently chief
financial officer of CytomX Therapeutics [NASDAQ: CTMX], where he
joined prior to their going public, and executed a late-stage
private offering and an initial public offering (IPO). Prior to
that, Bob was a finance executive for more than 11 years at Amgen
and Onyx Pharmaceuticals, an Amgen subsidiary. He also previously
served as an audit manager at Ernst and Young. Bob holds an MBA
from the UCLA Anderson School of Management.
Joining as general counsel is Tamara ("Tammy") L. Tompkins, JD.
Tammy was most recently general counsel, chief administrative
officer and operating partner at the $4
billion venture investing juggernaut Khosla Ventures, where
she was responsible for legal, financial, IR, and
operational/administrative matters and served on boards of several
portfolio companies. Prior to that, Tammy was general counsel at
Amyris where she helped navigate the company from inception through
IPO. Previously, she practiced law at Morgan, Lewis & Bockius,
as well as at Brobeck, Phleger & Harrison and Shearman &
Sterling. Tammy holds a juris doctor degree from Georgetown University.
Joining as senior vice president of operations is Doug Rich. Doug was most recently senior vice
president of operations at KYTHERA Biopharmaceuticals, responsible
for the company's manufacturing, supply chain and quality. Prior to
that, Doug was vice president of quality at Boeringer Ingelheim,
and held leadership positions during his 18 years at Amgen, both
within the quality organization and global operations. Doug holds
an MBA from Pepperdine University.
"We continue to be incredibly fortunate in our ability to
attract stellar talent that matches the level of promise of UNITY's
mission to attack diseases of aging and fundamentally reshape human
healthspan," said Keith Leonard,
UNITY chairman and CEO. "These key additions already have had a
major impact in driving this mission toward reality."
Departing the company from their interim positions are
John Smither as chief financial
officer and Keith Klein as general
counsel, both former KYTHERA executives who have been helping grow
and structure UNITY's efforts over the past 18 months. "We deeply
appreciate all the work done by both John and Keith to help
transition UNITY from a pure research effort into a
well-integrated, platform biotech company," said Leonard. "Having
access to such experienced talent in our early stages has been
critical to our impressive progress."
About UNITY Biotechnology
UNITY Biotechnology is
developing therapeutics that increase healthspan by preventing,
halting, or reversing diseases of aging. UNITY's initial focus is
on creating senolytic medicines to selectively eliminate senescent
cells and thereby treat age-related afflictions such as
osteoarthritis, atherosclerosis, eye diseases, and kidney disease.
Backed by a group of visionary investors, UNITY's world-class
management team has experience building companies and developing
medicines together: the team has collectively moved more than 90
therapeutic candidates into human clinical trials and developed 13
FDA-approved medicines. UNITY's mission is to build a future in
which it doesn't hurt to be old — a future in which people stay
healthy and mobile long into old age. More information is available
at www.unitybiotechnology.com.
View original content with
multimedia:http://www.prnewswire.com/news-releases/unity-biotechnology-appoints-additional-biotech-industry-veterans-to-executive-team-300522529.html
SOURCE UNITY Biotechnology